US Pharma MarketingThe post Abbott secures CE Mark for Cologuard Plus cancer test appeared first on Medical Device Network.
Abbott secures CE Mark for Cologuard Plus cancer test
Abbott has secured CE Mark approval under the European Union’s IVDR for its Cologuard Plus colorectal cancer screening test. The regulatory clearance enables Abbott to introduce the test across select European markets, subject to operational readiness. Designed for adults aged 45 and above at average risk, Cologuard Plus analyses stool samples for occult blood. Credit: Jo Panuwat D / Shutterstock.com. Abbott has secured CE Mark approval under the EU’s In Vitro Diagnostic Medical Devices Regulation (IVDR) for its Cologuard Plus colorectal cancer screening test. The regulatory clearance enables the company to introduce the noninvasive test across select European markets, with…
Abbott has secured CE Mark approval under the European Union’s IVDR for its Cologuard Plus colorectal cancer screening test.
Source: Medical Device Network